| Patent Number |
Title Of Patent |
Date Issued |
| 6271266 |
Use of idebenone and analogues against .beta. amyloid induced cytotoxicity |
August 7, 2001 |
| A compound of the formula: ##STR1##wherein R.sup.1 represents a lower alkyl; R.sup.2 represents H, an optionally substituted alkyl or an optionally substituted alkenyl; R.sup.3 and R.sup.4 each represents an optionally substituted lower alkyl or a lower alkoxy, or R.sup.3 and R.sup.4 |
| 6271243 |
Pharmaceutical composition |
August 7, 2001 |
| Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabe |
| 6268354 |
Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative |
July 31, 2001 |
| This invention is to provide a pharmaceutical composition for antagonizing CCR5 which comprises a compound of the formula: ##STR1##wherein R.sup.1 is an optionally substituted 5- to 6-membered ring; W is a divalent group of the formula: ##STR2##wherein the ring A is an optionally sub |
| 6267981 |
Method of producing sustained-release preparation |
July 31, 2001 |
| This invention provides a sustained-release preparation comprising a biodegradable polymer metal salt and broactive polypeptide, with enhanced entrapment of the bioactive polypeptides, a suppression of initial burst, and a constant long-term release of the bioactive polypeptides. |
| 6265586 |
Process for producing indolmycins |
July 24, 2001 |
| A process for producing indolmycin or a salt thereof which comprises reacting a compound of the formula: ##STR1##or a salt thereof with methylamine or a salt thereof, can be produced in an optically active form in a high yield and high quality, and is advantageous from the industrial |
| 6265582 |
Method for producing isoureas |
July 24, 2001 |
| The present invention relates to a method for producing a compound of the formula: ##STR1##wherein R.sup.1 is an optionally substituted hydrocarbon group; R.sup.2 is H or an optionally substituted hydrocarbon group; and Q is an optionally substituted heterocyclic group, or a salt the |
| 6264970 |
Sustained-release preparation |
July 24, 2001 |
| A sustained-release preparation comprising a bioactive substance having an acidic group and a biodegradable polymer having an optionally protected basic group which improves the rate of incorporation of the bioactive substance, suppresses its leakage early after administration, and exhib |
| 6262267 |
Thienopyridine compound |
July 17, 2001 |
| The compound of the present invention possesses excellent gonadotropin-releasing hormone antagonizing activity, and is useful for preventing or treating sex hormone-dependent diseases, e,g., sex hormone-dependent cancers (e.g., prostatic cancer, uterine cancer, breast cancer, pituita |
| 6258561 |
Method of producing a 19P2 ligand |
July 10, 2001 |
| The method of the present invention is suitable for the commercial high-level production of a protein or peptide which can be used as a prophylactic and therapeutic drug for various diseases such as senile dementia, cerebrovascular dementia (dementia arising from cerebrovascular diso |
| 6255529 |
Method of and apparatus for decomposing wastes |
July 3, 2001 |
| A method of decomposing wastes containing target compounds having one or more of hydrolyzable bonds of ether bond, ester bond, amide bond and isocyanate bond wherein the method comprises continuously supplying the wastes in a molten state or liquid state to a reactor, continuously su |
| 6255433 |
One-package thixotropic polyurethane resin composition |
July 3, 2001 |
| A one-package thixotropic polyurethane resin composition comprising 10 to 90% by weight of a urethane prepolymer having a terminal free isocyanate group(a) which is obtained by reacting a polyisocyanate(b) with a compound having two or more active hydrogens(c), a monool(d) and an (N- |
| 6251926 |
Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity |
June 26, 2001 |
| This invention provides a novel oxyiminoalkanoic acid derivative which has excellent hypoglycemic and hypolipidemic actions and which is used for the treatment of diabetes mellitus, hyperlipemia, insulin insensitivity, insulin resistance and impaired glucose tolerance. |
| 6251924 |
Pharmaceutical composition |
June 26, 2001 |
| Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in he mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabet |
| 6251905 |
Tricyclic compounds, their production and use |
June 26, 2001 |
| Tricyclic compound of the formula: ##STR1##wherein ring A is a nitrogen-containing heterocyclic ring, having two nitrogen atoms as the hetero-atoms, which is optionally substituted with oxo or thioxo; ring Q may optionally be substituted;Y is an optionally substituted hydrocarbon group, |
| 6251861 |
Treatment of cerebral infarction using cyclic hexapeptides |
June 26, 2001 |
| A pharmaceutical composition comprising a compound having anti-endothelin activity is useful for the prophylaxis or treatment of cerebral infarction. |
| 6251612 |
Monoclonal antibody for immunoassay of detergents and their degradation products and its use |
June 26, 2001 |
| A hybridoma obtainable by fusing a spleen cell or lymphocyte of an animal immunized by a complex of a surfactant compound for synthetic detergent and protein with a myeloma cell, which produces a monoclonal antibody against the compound or its degradation product. A monoclonal antibody |
| 6248766 |
Tricyclic compounds, their production and use |
June 19, 2001 |
| A compound of the formula: ##STR1##wherein R.sup.1 is H or a substituent; m is 1-3; Ar is an aromatic group which may be substituted; X is a bond or a divalent straight-chain group having 1-6 atoms which may be substituted; Y is --S--, --O--, or --N(R.sup.2 -- (R.sup.2 is H or a subs |
| 6248740 |
Condensed pyridazine derivatives, their production and use |
June 19, 2001 |
| The present invention provides a compound represented by the formula: ##STR1##wherein Ar.sup.1 and Ar.sup.2 are independently an aromatic group which may be substituted, and Ar.sup.1 and Ar.sup.2 may form a condensed cyclic group with an adjacent carbon atom; ring B is a nitrogen-contain |
| 6248357 |
Solid pharmaceutical preparation with improved buccal disintegrability and/or dissolubility |
June 19, 2001 |
| A solid pharmaceutical preparation comprising a pharmaceutically active ingredient, erythritol, crystalline cellulose and an disintegrants, which exhibits a fast buccal disintegratability and dissolubility. |
| 6245419 |
Resin composition having excellent vibration-damping properties and molded article made thereof |
June 12, 2001 |
| An unsaturated polyester resin composition having excellent vibration-damping properties, comprising an unsaturated polyester resin (A) having a glass transition temperature (Tg) of 0.degree. C. or more and less than 60.degree. C. In the composition, the unsaturated polyester resin ( |
| 6245351 |
Controlled-release composition |
June 12, 2001 |
| A controlled-release composition comprising a drug-containing core coated with a coating composition containing a water-insoluble substance and a swellable polymer having no basic groups which is capable of maintaining an almost constant drug concentration in plasma over an extended peri |
| 6242600 |
2-piperazinone-1-acetic acid derivatives and their use |
June 5, 2001 |
| The present invention provides compounds and medicines effective for prophylaxis and therapy of various diseases by controlling or inhibiting cell-adhesion. Especially, the compounds of this invention inhibit platelet aggregation action without remarkable elongation of hemorrhagic pe |
| 6242471 |
Condensed 4,5,6,7-tetrahydrobenzo[C]thiophenes as enhancer for cell differentiation induction fa |
June 5, 2001 |
| A compound represented by the formula: ##STR1##wherein X represents a sulfur atom or an oxygen atom; Y represents an optionally oxidized sulfur atom or an oxygen atom; Z represents a bond or a divalent hydrocarbon group; R.sup.1 represents an optionally substituted hydrocarbon group; |
| 6239215 |
Powder coating composition |
May 29, 2001 |
| A powder coating composition comprising a multilayer polymer particle, in which at least one inner layer is a polymer layer having a glass transition temperature (Tg) of not over 20.degree. C. and the outermost layer is a polymer layer having a Tg of not less than 60.degree. C. and, |
| 6239153 |
Pharmaceutical composition |
May 29, 2001 |
| Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabe |
| 6235947 |
D-mannitol and its preparation |
May 22, 2001 |
| D-mannitol having a specific surface area of not less than about 1 m.sup.2 /g is disclosed. The D-mannitol shows improved compressibility and is useful as an excipient. |
| 6235878 |
Fas ligand-like protein, its production and use |
May 22, 2001 |
| This invention is directed toward novel human and murine Fas ligand-like proteins having an apoptosis-inducing activity. Cloned cDNAs encoding human, mouse, and rat Fas ligand-like proteins were obtained from human liver, mouse embryo, and rat liver cDNA libraries. The cDNAs were exp |
| 6235789 |
Benzocycloalkene compounds, their production and use |
May 22, 2001 |
| A compound of the formula ##STR1##wherein R.sup.1 and R.sup.2 are H, a hydrocarbon group or a heterocyclic group, or R.sup.1 and R.sup.2 are combinedly a spiro ring; R.sup.3 is a hydrocarbon group, a substituted amino group, a substituted hydroxyl group or a heterocyclic group; R.sup |
| 6235771 |
Anilide derivative, production and use thereof |
May 22, 2001 |
| This invention is to provide a compound of the formula: ##STR1##wherein R.sup.1 is an optionally substituted 5- to 6-membered ring; the ring A is an optionally substituted 6- to 7-membered ring; the ring B is an optionally substituted benzene ring; n is an integer of 1 or 2; Z is a c |
| 6235731 |
Fused imidazopyridine derivatives as antihyperlipidemic agents |
May 22, 2001 |
| A novel compound of the formula: ##STR1##wherein ring Q is an optionally substituted pyridine ring;One of R.sup.0, R.sup.1 and R.sup.2 is --Y.sup.0 --Z.sup.0, and the other tow groups are a hydrogen, a halogen, an optionally substituted hydroxy group, a hydrocarbon group that may be an o |
| 6232334 |
Benzimidazole derivatives, their production and use |
May 15, 2001 |
| Benzimidazole derivatives of the formula (I): ##STR1##wherein the ring A is a benzene ring which may optionally contain substitution in addition to the R' group; R.sup.1 is hydrogen or an optionally substituted hydrocarbon residue; R.sup.2 is a group capable of forming an anion or a |
| 6232330 |
Pharmaceutical composition |
May 15, 2001 |
| Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabe |
| 6232288 |
Composition for improving pancreatic function |
May 15, 2001 |
| The present invention provides a novel composition comprising a betacellulin protein, or a fragment thereof, which is capable of promoting the differentiation of undifferentiated pancreatic cells into insulin-producing beta cells or pancreatic polypeptide producing F cells. This comp |
| 6228984 |
Polypeptides their production and use |
May 8, 2001 |
| The present invention relates to the ligand polypeptide for the human pituitary- and mouse pancreas-derived G protein-coupled receptor proteins. The ligand polypeptide or the DNA which codes for the ligand polypeptide can be used for (1) development of medicines such as pituitary functio |
| 6228874 |
Pharmaceutical composition for angiotensin II-mediated diseases |
May 8, 2001 |
| This invention relates to a pharmaceutical composition for angiotensin II-mediated diseases, which comprises a compound having angiotensin II antagonistic activity of the formula ##STR1##wherein R.sup.1 is H or an optionally substituted hydrocarbon residue; R.sup.2 is an optionally e |
| 6225326 |
Pharmaceutical composition |
May 1, 2001 |
| Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabe |
| 6224568 |
Dual-chamber type injector and connector used therefor |
May 1, 2001 |
| A needle connecting portion of a syringe which includes a drug accommodating chamber accommodating a first component is arranged opposite to a takeout port of a hermetically closed container which includes a container chamber accommodating a second component. The syringe is connected |
| 6221995 |
Modified polyisocyanate and production process thereof |
April 24, 2001 |
| A modified polyisocyanate which has a high emulsifying/dispersing ability in aqueous resin compositions (solution or dispersion) and can be used advantageously as a curing agent or cross-linking agentis disclosed. The modified polyisocyanate is comprised of a reaction product of a po |
| 6221637 |
Xanthene derivatives, their production and use |
April 24, 2001 |
| Xanthene compounds represented by the formula: ##STR1##wherein R.sup.1 is a carboxyl group which may be esterified or amidated; R.sup.2 is a hydrogen atom, a hydroxyl group, or a hydrocarbon group which may be substituted; R.sup.3 and R.sup.4 are the same or different and are a hydro |
| 6218509 |
LH/CG receptor, DNA and use thereof |
April 17, 2001 |
| Disclosed are (1) a human luteinizing hormone-human chorionic gonadotropin receptor protein, (2) a DNA comprising a cDNA segment coding for a human luteinizing hormone-human chorionic gonadotropin receptor protein, (SEQ ID NO:2) (3) a transformant carrying a DNA comprising a cDNA segment |
| 6218429 |
Tricyclic compounds, their production and use |
April 17, 2001 |
| A compound of the formula: ##STR1##wherein R.sup.1 is an optionally substituted hydrocarbon, amino or heterocyclic group; R.sup.2 is H or an optionally substituted hydrocarbon group; R.sup.3 is H or an optionally substituted hydrocarbon or heterocyclic group; X is CHR.sup.4, NR.sup.4 |
| 6218409 |
Pharmaceutical composition |
April 17, 2001 |
| Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabe |
| 6214848 |
Pharmaceutical composition |
April 10, 2001 |
| Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabe |
| 6214838 |
Thienodipyridine derivatives, production and use thereof |
April 10, 2001 |
| A compound of the formula (I): ##STR1##wherein R is hydrogen or C.sub.2-6 alkanoyl; X is halogen; and ring A is benzene ring which is optionally substituted by 1 to 4 substituents selected from 1 halogen, 2 hydroxy, 3 C.sub.1-6 alkoxy optionally substituted by halogen or phenyl, 4 C. |
| 6211333 |
Method for producing peptides and their salts which have an agonist activity of luteinizing horm |
April 3, 2001 |
| A peptide of the formula:wherein R.sup.1 represents His, Tyr, Trp or p--NH.sub.2 --Phe, R.sup.2 represents Tyr or Phe, R.sup.3 represents an optionally substituted Gly or an optionally substituted .alpha.-D-amino acid residue, R.sup.4 represents Leu, Ile or Nle, R.sup.6 represents (1) Gl |
| 6211215 |
Heterocyclic compounds, their production and use |
April 3, 2001 |
| Heterocyclic compounds represented by the general formula (I) ##STR1##wherein R stands for an optionally substituted aromatic heterocyclic group;X stands for oxygen atom, an optionally oxidated sulfur atom, --C(.dbd.O)-- or --CH(OH)--;Y stands for CH or N;m denotes an integer of 0 to 10:n de |
| 6211207 |
Pharmaceutical composition |
April 3, 2001 |
| Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabe |
| 6211206 |
Pharmaceutical composition |
April 3, 2001 |
| Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabe |
| 6211205 |
Pharmaceutical composition |
April 3, 2001 |
| Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabe |
| 6211178 |
Triazine derivative, production and use thereof |
April 3, 2001 |
| The present invention provides a novel triazine derivative of the formula ##STR1##wherein ring A is an optionally substituted aromatic group which be;X is an oxygen or sulfur atom;R.sup.1 and R.sup.6 are each a hydrogen atom or an optionally substituted hydrocarbon residue or heterocyclic gr |
